ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Civica, Blue Cross Blue Shield create generic drug subsidiary

by Lisa M. Jarvis
February 1, 2020 | APPEARED IN VOLUME 98, ISSUE 5

 

Civica Rx, a nonprofit formed in 2018 by health systems and philanthropies to stabilize the supply of generic drugs, continues its rapid growth. Days after announcing a manufacturing partnership with Thermo Fisher Scientific, Civica has teamed with Blue Cross Blue Shield Association to create a subsidiary dedicated to lowering the cost of certain generic drugs. Blue Cross has committed $55 million to the subsidiary, which will acquire abbreviated new-drug applications for select high-cost products that it aims to make available by early 2022.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment